Publicaciones (96) Publicaciones en las que ha participado algún/a investigador/a

2019

  1. A novel concept to include uncertainties in the evaluation of stereotactic body radiation therapy after 4D dose accumulation using deformable image registration

    Medical Physics, Vol. 46, Núm. 10, pp. 4346-4355

  2. A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1754-1762

  3. Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival

    BMC Cancer, Vol. 19, Núm. 1

  4. Agnostic-histology approval of new drugs in oncology: Are we already there?

    Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3210-3219

  5. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087

  6. Apoptotic caspases cut down the immunogenicity of radiation

    OncoImmunology, Vol. 8, Núm. 11

  7. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

    OncoImmunology, Vol. 8, Núm. 11

  8. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  9. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach

    British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683

  10. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  11. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  12. Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study

    Medical Oncology, Vol. 36, Núm. 3

  13. Chemotherapy-free treatments: Are we ready for prime time?

    Annals of Oncology

  14. Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

    Actas Dermo-Sifiliograficas, Vol. 110, Núm. 6, pp. 448-459

  15. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 21, Núm. 5, pp. 556-571

  16. Clinical presentation, diagnosis and staging of cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 98-107

  17. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  18. Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis

    Clinical Chemistry and Laboratory Medicine, Vol. 57, Núm. 10, pp. 1539-1545

  19. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

  20. Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))

    European Urology